Feed aggregator

Bayer to accelerate drug discovery with Google Cloud's high-performance compute power

World Pharma News - Thu, 01/12/2023 - 11:00
Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run cutting-edge machine learning models and computationally-intensive workloads, to help accelerate and scale Bayer's quantum chemistry calculations.

Nanotechnology may improve gene therapy for blindness

World Pharma News - Wed, 01/11/2023 - 11:00
Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness.

A collaborative team of researchers with Oregon Health & Science University and Oregon State University have developed an approach that uses lipid nanoparticles - tiny, lab-made balls of fat - to deliver strands of messenger ribonucleic acid, or mRNA, inside the eye.

NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs

World Pharma News - Tue, 01/10/2023 - 11:00
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline

World Pharma News - Mon, 01/09/2023 - 11:00
AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.

FDA grants Accelerated Approval for Alzheimer's disease treatment

World Pharma News - Fri, 01/06/2023 - 11:00
Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer's disease. Leqembi is the second of a new category of medications approved for Alzheimer's disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease.

Incurable liver disease may prove curable

World Pharma News - Thu, 01/05/2023 - 11:00
Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the liver, could be reversed with a single drug. The study, published in the Proceedings of the National Academy of Sciences, has the potential to transform treatment for this rare disease and may also have implications for more common diseases.

Scientists develop a cancer vaccine to simultaneously kill and prevent brain cancer

World Pharma News - Wed, 01/04/2023 - 11:00
Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, investigators have developed a new cell therapy approach to eliminate established tumors and induce long-term immunity, training the immune system so that it can prevent cancer from recurring.

Time-restricted eating reshapes gene expression throughout the body

World Pharma News - Tue, 01/03/2023 - 11:00
Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a hot topic in the wellness industry. However, exactly how it affects the body on the molecular level, and how those changes interact across multiple organ systems, has not been well understood.

Chroma Scores $135M for Epigenetic Editing Approach

Biospace news - Tue, 01/03/2023 - 02:00
Chroma Scores $135M for Epigenetic Editing Approach 3/1/2023

FDA Rejects Cytokinetics’ Heart Failure Drug, Requests Another Trial

Biospace news - Tue, 01/03/2023 - 02:00
FDA Rejects Cytokinetics’ Heart Failure Drug, Requests Another Trial 3/1/2023

Keytruda Offsets Back-to-Back Flops with Phase III NSCLC Win

Biospace news - Tue, 01/03/2023 - 02:00
Keytruda Offsets Back-to-Back Flops with Phase III NSCLC Win 3/1/2023

Novavax Warns Investors it May Not be Able to Continue Operations

Biospace news - Tue, 01/03/2023 - 02:00
Novavax Warns Investors it May Not be Able to Continue Operations 3/1/2023

Economic Constriction has Fallout on Investments, IPOs and Collaborations

Biospace news - Tue, 01/03/2023 - 02:00
Economic Constriction has Fallout on Investments, IPOs and Collaborations 3/1/2023

FDA Approves First Therapy for Friedreich's Ataxia (Updated)

Biospace news - Tue, 01/03/2023 - 02:00
FDA Approves First Therapy for Friedreich's Ataxia (Updated) 3/1/2023

COVID-19 vaccines, prior infection reduce transmission of Omicron

World Pharma News - Mon, 01/02/2023 - 11:00
Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by researchers at UC San Francisco that examined transmission between people living in the same cell.

Enzyme that protects against viruses could fuel cancer evolution

World Pharma News - Fri, 12/30/2022 - 11:00
An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a study led by investigators at Weill Cornell Medicine. The finding suggests that the enzyme may be a potential target for future cancer treatments.

Pfizer announces positive top-line results from Phase 3 study of hemophilia B gene therapy candidate

World Pharma News - Thu, 12/29/2022 - 11:00
Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B.

VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain

World Pharma News - Wed, 12/28/2022 - 11:00
GSK plc (LSE/NYSE: GSK) has announced the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) authorised Sanofi's SARS-CoV-2 spike protein (B.1.351 strain) vaccine for the prevention of COVID-19 disease in adults aged 18 and above in Great Britain, following the European Commission licence last month, which included Northern Ireland.

High levels of ammonia in colon tumors inhibits T cell growth and response to immunotherapy

World Pharma News - Tue, 12/27/2022 - 11:00
High levels of ammonia in tumors leads to fewer T cells and immunotherapy resistance in mouse models of colorectal cancer, new findings from the University of Michigan Rogel Cancer Center revealed. Researchers found that ammonia inhibits the growth and function of T cells, which are vital for anti-tumor immunity. The findings appear in Cell Metabolism.